Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial - Elmets, Craig A.; Viner, Jaye L.; Pentland, Alice P.; Cantrell, Wendy; Lin, Hui-Yi; Bailey, Howard; Kang, Sewon; Linden, Kenneth G.; Heffernan, Michael; Duvic, Madeleine; Richmond, Ellen; Elewski, Boni E.; et al. (JNCI : Journal of the National Cancer Institute, 2010)
Keywords: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents - administration & dosage; Anticarcinogenic Agents - adverse effects; Anticarcinogenic Agents - therapeutic use; Biological and medical sciences; Carcinoma, Basal Cell - prevention & control; Carcinoma, Squamous Cell - prevention & control; Celecoxib; Cell Transformation, Neoplastic; Chemotherapy; Clinical trials; Cyclooxygenase 2 Inhibitors - therapeutic use; Dermatology; Double-Blind Method; Female; Humans; Inhibitor drugs; Keratosis, Actinic - drug therapy; Keratosis, Actinic - pathology; Male; Medical sciences; Middle Aged; Oncology; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Skin cancer; Skin Neoplasms - etiology; Skin Neoplasms - prevention & control; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Treatment Outcome; Tumors; Tumors of the skin and soft tissue. Premalignant lesions; United States; North America; America; Human; Prostaglandin-endoperoxide synthase; Skin disease; Chemoprophylaxis; Enzyme; Enzyme inhibitor; Cyclooxygenase 2 inhibitor; Malignant tumor; Celecoxib; Randomized controlled trial; Skin cancer; Prevention; Cancerology; Double blind study; Oxidoreductases; Public health; Cancer